China Antibody Pharmaceutical

SinoMab BioScience is a Hong Kong-based biopharmaceutical company dedicated to the discovery, development, and commercialization of antibody-based therapeutics for immunological diseases. The company's flagship product, Suciraslimab (SM03), is a first-in-class anti-CD22 monoclonal antibody currently under NDA review in China for the treatment of rheumatoid arthritis. SinoMab's pipeline includes a variety of biologics and small molecules targeting B-cell and T-cell mediated pathways to address unmet medical needs in autoimmune and inflammatory conditions. With integrated capabilities spanning R&D, clinical development, and GMP-certified manufacturing, the company is positioned as a leader in the Greater Bay Area's biotechnology sector. SinoMab aims to provide innovative and affordable therapeutic solutions to patients suffering from chronic immunological disorders globally.